Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Accumulated Expenses (2016 - 2025)

ImmunityBio (IBRX) has disclosed Other Accumulated Expenses for 12 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 192.67% to $3.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 million, a 192.67% increase, with the full-year FY2025 number at $3.1 million, up 192.67% from a year prior.
  • Other Accumulated Expenses was $3.1 million for Q4 2025 at ImmunityBio, up from $2.1 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $3.1 million in Q4 2025 to a low of $556000.0 in Q1 2024.
  • A 5-year average of $1.6 million and a median of $1.4 million in 2024 define the central range for Other Accumulated Expenses.
  • Biggest YoY gain for Other Accumulated Expenses was 702.7% in 2021; the steepest drop was 70.56% in 2021.
  • ImmunityBio's Other Accumulated Expenses stood at $2.6 million in 2021, then plummeted by 37.26% to $1.6 million in 2022, then crashed by 56.02% to $716000.0 in 2023, then skyrocketed by 46.65% to $1.0 million in 2024, then skyrocketed by 192.67% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Other Accumulated Expenses are $3.1 million (Q4 2025), $2.1 million (Q3 2025), and $1.9 million (Q2 2025).